{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:20:14Z","timestamp":1790432414671,"version":"4.1.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["ERC-2013-CoG 614739-A_HERO"],"award-info":[{"award-number":["ERC-2013-CoG 614739-A_HERO"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40249-017-0286-2","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T07:26:15Z","timestamp":1490685975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?"],"prefix":"10.1186","volume":"6","author":[{"given":"Robert","family":"Bergquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"Utzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"issue":"2","key":"286_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.idc.2012.03.004","volume":"26","author":"B Gryseels","year":"2012","unstructured":"Gryseels B. Schistosomiasis. Infect Dis Clin North Am. 2012;26(2):383\u201397.","journal-title":"Infect Dis Clin North Am"},{"issue":"9936","key":"286_CR2","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","volume":"383","author":"DG Colley","year":"2014","unstructured":"Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383(9936):2253\u201364.","journal-title":"Lancet"},{"issue":"11","key":"286_CR3","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1371\/journal.pmed.0020336","volume":"2","author":"DH Molyneux","year":"2005","unstructured":"Molyneux DH, Hotez PJ, Fenwick A. \u201cRapid-impact interventions\u201d: how a policy of integrated control for Africa\u2019s neglected tropical diseases could benefit the poor. PLoS Med. 2005;2(11):e336.","journal-title":"PLoS Med"},{"key":"286_CR4","first-page":"w13727","volume":"142","author":"J Utzinger","year":"2012","unstructured":"Utzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J, Hatz CF. Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med Wkly. 2012;142:w13727.","journal-title":"Swiss Med Wkly"},{"key":"286_CR5","doi-asserted-by":"crossref","unstructured":"GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease study 2015. Lancet 2016;388(10053):1603\u201358.","DOI":"10.1016\/S0140-6736(16)31460-X"},{"issue":"9470","key":"286_CR6","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)66457-4","volume":"365","author":"CH King","year":"2005","unstructured":"King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365(9470):1561\u20139.","journal-title":"Lancet"},{"issue":"1","key":"286_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1742395307084407","volume":"4","author":"CH King","year":"2008","unstructured":"King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn. 2008;4(1):65\u201379.","journal-title":"Chronic Illn"},{"issue":"7","key":"286_CR8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002865","volume":"8","author":"PJ Hotez","year":"2014","unstructured":"Hotez PJ, Alvarado M, Bas\u00e1\u00f1ez MG, Bolliger I, Bourne R, Boussinesq M, Brooker SJ, Brown AS, Buckle G, Budke CM, et al. The Global Burden of Disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8(7):e2865.","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl 1","key":"286_CR9","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.actatropica.2010.08.020","volume":"120","author":"J Utzinger","year":"2011","unstructured":"Utzinger J, N\u2019Goran EK, Caffrey CR, Keiser J. From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop. 2011;120 Suppl 1:S121\u201337.","journal-title":"Acta Trop"},{"issue":"8","key":"286_CR10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(15)00066-3","volume":"15","author":"YS Lai","year":"2015","unstructured":"Lai YS, Biedermann P, Ekpo UF, Garba A, Mathieu E, Midzi N, Mwinzi P, N\u2019Goran EK, Raso G, Assar\u00e9 RK, et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. Lancet Infect Dis. 2015;15(8):927\u201340.","journal-title":"Lancet Infect Dis"},{"key":"286_CR11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.actatropica.2013.12.007","volume":"132","author":"RGC Scholte","year":"2014","unstructured":"Scholte RGC, Gosoniu L, Malone JB, Chammartin F, Utzinger J, Vounatsou P. Predictive risk mapping of schistosomiasis in Brazil using Bayesian geostatistical models. Acta Trop. 2014;132:57\u201363.","journal-title":"Acta Trop"},{"key":"286_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(10)72001-7","volume":"72","author":"J Utzinger","year":"2010","unstructured":"Utzinger J, Bergquist R, Olveda R, Zhou XN. Important helminth infections in Southeast Asia: diversity, potential for control and prospects for elimination. Adv Parasitol. 2010;72:1\u201330.","journal-title":"Adv Parasitol"},{"issue":"9","key":"286_CR13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1471-4922(03)00193-4","volume":"19","author":"LA Tchuem Tchuent\u00e9","year":"2003","unstructured":"Tchuem Tchuent\u00e9 LA, Southgate VR, Jourdane J, Webster BL, Vercruysse J. Schistosoma intercalatum: an endangered species in Cameroon? Trends Parasitol. 2003;19(9):389\u201393.","journal-title":"Trends Parasitol"},{"key":"286_CR14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0065-308X(10)72007-8","volume":"72","author":"S Muth","year":"2010","unstructured":"Muth S, Sayasone S, Odermatt-Biays S, Phompida S, Duong S, Odermatt P. Schistosoma mekongi in Cambodia and Lao People\u2019s Democratic Republic. Adv Parasitol. 2010;72:179\u2013203.","journal-title":"Adv Parasitol"},{"issue":"2\u20133","key":"286_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0001-706X(03)00029-9","volume":"86","author":"MJ Werf van der","year":"2003","unstructured":"van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003;86(2\u20133):125\u201339.","journal-title":"Acta Trop"},{"key":"286_CR16","volume-title":"Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers","author":"WHO","year":"2006","unstructured":"WHO. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization; 2006."},{"issue":"39","key":"286_CR17","first-page":"456","volume":"91","author":"WHO","year":"2016","unstructured":"WHO. Summary of global update on preventive chemotherapy implementation in 2015. Wkly Epidemiol Rec. 2016;91(39):456\u20139.","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"286_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00389899","volume":"52","author":"R G\u00f6nnert","year":"1977","unstructured":"G\u00f6nnert R, Andrews P. Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd. 1977;52(2):129\u201350.","journal-title":"Z Parasitenkd"},{"issue":"6","key":"286_CR19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QCO.0b013e328318978f","volume":"21","author":"MJ Doenhoff","year":"2008","unstructured":"Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659\u201367.","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"286_CR20","first-page":"767","volume":"57","author":"A Davis","year":"1979","unstructured":"Davis A, Wegner DH. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ. 1979;57(5):767\u201371.","journal-title":"Bull World Health Organ"},{"key":"286_CR21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1996.55.214","volume":"55","author":"M Ismail","year":"1996","unstructured":"Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL. Characterisation of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg. 1996;55:214\u20138.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"286_CR22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/expr.1997.4149","volume":"86","author":"PG Fallon","year":"1997","unstructured":"Fallon PG, Mubarak JS, Fookes RE, Niang M, Butterworth AE, Sturrock RF, Doenhoff MJ. Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. Exp Parasitol. 1997;86(1):29\u201336.","journal-title":"Exp Parasitol"},{"issue":"8","key":"286_CR23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000504","volume":"3","author":"SD Melman","year":"2009","unstructured":"Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3(8):e504.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"286_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14656566.5.2.263","volume":"5","author":"J Utzinger","year":"2004","unstructured":"Utzinger J, Keiser J. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother. 2004;5(2):263\u201385.","journal-title":"Expert Opin Pharmacother"},{"key":"286_CR25","first-page":"CD000528","volume":"2","author":"A Danso-Appiah","year":"2013","unstructured":"Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev. 2013;2:CD000528.","journal-title":"Cochrane Database Syst Rev"},{"key":"286_CR26","volume":"3","author":"A Danso-Appiah","year":"2008","unstructured":"Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2008;3:CD000053.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"286_CR27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00003495-199142030-00004","volume":"42","author":"KC Shekhar","year":"1991","unstructured":"Shekhar KC. Schistosomiasis drug therapy and treatment considerations. Drugs. 1991;42(3):379\u2013405.","journal-title":"Drugs"},{"issue":"11","key":"286_CR28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1586\/14787210.2013.844066","volume":"11","author":"S Knopp","year":"2013","unstructured":"Knopp S, Becker SL, Ingram KJ, Keiser J, Utzinger J. Diagnosis and treatment of schistosomiasis in children in the era of intensified control. Expert Rev Anti Infect Ther. 2013;11(11):1237\u201358.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"286_CR29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.actatropica.2012.04.013","volume":"128","author":"D Rollinson","year":"2013","unstructured":"Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuent\u00e9 LA, Garba A, Mohammed KA, Schur N, Person B, Colley DG, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop. 2013;128(2):423\u201340.","journal-title":"Acta Trop"},{"key":"286_CR30","volume-title":"Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation","author":"WHO","year":"2012","unstructured":"WHO. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva: World Health Organization; 2012."},{"issue":"12","key":"286_CR31","volume":"8","author":"JET Grimes","year":"2014","unstructured":"Grimes JET, Croll D, Harrison WE, Utzinger J, Freeman MC, Templeton MR. The relationship between water, sanitation and schistosomiasis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2014;8(12):e3296.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"286_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004794","volume":"10","author":"SH Sokolow","year":"2016","unstructured":"Sokolow SH, Wood CL, Jones IJ, Swartz SJ, Lopez M, Hsieh MH, Lafferty KD, Kuris AM, Rickards C, De Leo GA. Global assessment of schistosomiasis control over the past century shows targeting the snail intermediate host works best. PLoS Negl Trop Dis. 2016;10(7):e0004794.","journal-title":"PLoS Negl Trop Dis"},{"key":"286_CR33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0065-308X(10)73008-6","volume":"73","author":"J Keiser","year":"2010","unstructured":"Keiser J, Utzinger J. The drugs we have and the drugs we need against major helminth infections. Adv Parasitol. 2010;73:197\u2013230.","journal-title":"Adv Parasitol"},{"issue":"6","key":"286_CR34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2214-109X(13)70078-0","volume":"1","author":"B Pedrique","year":"2013","unstructured":"Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, Ford N, P\u00e9coul B, Bradol J-H. The drug and vaccine landscape for neglected diseases (2000\u201311): a systematic assessment. Lancet Glob Health. 2013;1(6):371\u2013e379.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"286_CR35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/CMR.13.2.207-222.2000","volume":"13","author":"S Geerts","year":"2000","unstructured":"Geerts S, Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev. 2000;13(2):207\u201322.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"286_CR36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/femsre\/fuw037","volume":"41","author":"CJ Woodrow","year":"2017","unstructured":"Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41(1):34\u201348.","journal-title":"FEMS Microbiol Rev"},{"issue":"3","key":"286_CR37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S0031182009991739","volume":"137","author":"J Keiser","year":"2010","unstructured":"Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2010;137(3):589\u2013603.","journal-title":"Parasitology"},{"key":"286_CR38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0065-308X(01)50032-9","volume":"50","author":"S Tagboto","year":"2001","unstructured":"Tagboto S, Townson S. Antiparasitic properties of medicinal plants and other naturally occurring products. Adv Parasitol. 2001;50:199\u2013295.","journal-title":"Adv Parasitol"},{"issue":"11","key":"286_CR39","doi-asserted-by":"crossref","first-page":"12771","DOI":"10.3390\/molecules171112771","volume":"17","author":"M Wink","year":"2012","unstructured":"Wink M. Medicinal plants: a source of anti-parasitic secondary metabolites. Molecules. 2012;17(11):12771\u201391.","journal-title":"Molecules"},{"issue":"2\u20133","key":"286_CR40","first-page":"215","volume":"38","author":"A Marston","year":"1993","unstructured":"Marston A, Maillard M, Hostettmann K. Search for antifungal, molluscicidal and larvicidal compounds from African medicinal plants. J Ethnopharmacol. 1993;38(2\u20133):215\u201323.","journal-title":"J Ethnopharmacol"},{"issue":"21","key":"286_CR41","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1016\/j.bmc.2014.07.014","volume":"22","author":"AY Spivak","year":"2014","unstructured":"Spivak AY, Keiser J, Vargas M, Gubaidullin RR, Nedopekina DA, Shakurova ER, Khalitova RR, Odinokov VN. Synthesis and activity of new triphenylphosphonium derivatives of betulin and betulinic acid against Schistosoma mansoni in vitro and in vivo. Bioorg Med Chem. 2014;22(21):6297\u2013304.","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"286_CR42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4155\/fmc.15.23","volume":"7","author":"J Moraes de","year":"2015","unstructured":"de Moraes J. Natural products with antischistosomal activity. Future Med Chem. 2015;7(6):801\u201320.","journal-title":"Future Med Chem"},{"issue":"2","key":"286_CR43","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3390\/molecules20021872","volume":"20","author":"BJ Neves","year":"2015","unstructured":"Neves BJ, Andrade CH, Cravo PV. Natural products as leads in schistosome drug discovery. Molecules. 2015;20(2):1872\u2013903.","journal-title":"Molecules"},{"issue":"1","key":"286_CR44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/14789450.2016.1116390","volume":"13","author":"P Driguez","year":"2016","unstructured":"Driguez P, McManus DP, Gobert GN. Clinical implications of recent findings in schistosome proteomics. Expert Rev Proteomics. 2016;13(1):19\u201333.","journal-title":"Expert Rev Proteomics"},{"issue":"7253","key":"286_CR45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature08160","volume":"460","author":"M Berriman","year":"2009","unstructured":"Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, et al. The genome of the blood fluke Schistosoma mansoni. Nature. 2009;460(7253):352\u20138.","journal-title":"Nature"},{"issue":"2","key":"286_CR46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng.1065","volume":"44","author":"ND Young","year":"2012","unstructured":"Young ND, Jex AR, Li B, Liu S, Yang L, Xiong Z, Li Y, Cantacessi C, Hall RS, Xu X, et al. Whole-genome sequence of Schistosoma haematobium. Nat Genet. 2012;44(2):221\u20135.","journal-title":"Nat Genet"},{"issue":"6","key":"286_CR47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4155\/fmc.15.21","volume":"7","author":"LG Ferreira","year":"2015","unstructured":"Ferreira LG, Oliva G, Andricopulo AD. Target-based molecular modeling strategies for schistosomiasis drug discovery. Future Med Chem. 2015;7(6):753\u201364.","journal-title":"Future Med Chem"},{"issue":"3","key":"286_CR48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pt.2009.12.006","volume":"26","author":"JP Webster","year":"2010","unstructured":"Webster JP, Oliviera G, Rollinson D, Gower CM. Schistosome genomes: a wealth of information. Trends Parasitol. 2010;26(3):103\u20136.","journal-title":"Trends Parasitol"},{"issue":"24","key":"286_CR49","first-page":"3531","volume":"18","author":"J Keiser","year":"2012","unstructured":"Keiser J, Utzinger J. Antimalarials in the treatment of schistosomiasis. Curr Pharm Des. 2012;18(24):3531\u20138.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"286_CR50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpddr.2014.07.002","volume":"4","author":"G Panic","year":"2014","unstructured":"Panic G, Duthaler U, Speich B, Keiser J. Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist. 2014;4(3):185\u2013200.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"5","key":"286_CR51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2174\/092986711794480096","volume":"18","author":"A Mullner","year":"2011","unstructured":"Mullner A, Helfer A, Kotlyar D, Oswald J, Efferth T. Chemistry and pharmacology of neglected helminthic diseases. Curr Med Chem. 2011;18(5):767\u201389.","journal-title":"Curr Med Chem"},{"issue":"9","key":"286_CR52","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1128\/AAC.33.9.1557","volume":"33","author":"SH Xiao","year":"1989","unstructured":"Xiao SH, Catto BA. In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob Agents Chemother. 1989;33(9):1557\u201362.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"286_CR53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0035-9203(02)90110-0","volume":"96","author":"J Utzinger","year":"2002","unstructured":"Utzinger J, Chollet J, Tu ZW, Xiao SH, Tanner M. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Trans R Soc Trop Med Hyg. 2002;96(3):318\u201323.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"286_CR54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ar7000843","volume":"41","author":"B Meunier","year":"2008","unstructured":"Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res. 2008;41(1):69\u201377.","journal-title":"Acc Chem Res"},{"issue":"11","key":"286_CR55","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1128\/AAC.00640-09","volume":"53","author":"J Boissier","year":"2009","unstructured":"Boissier J, Cosledan F, Robert A, Meunier B. In vitro activities of trioxaquines against Schistosoma mansoni. Antimicrob Agents Chemother. 2009;53(11):4903\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"286_CR56","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00082-11","volume":"55","author":"V Pradines","year":"2011","unstructured":"Pradines V, Portela J, Boissier J, Cosledan F, Meunier B, Robert A. Trioxaquine PA1259 alkylates heme in the blood-feeding parasite Schistosoma mansoni. Antimicrob Agents Chemother. 2011;55(5):2403\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"286_CR57","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1128\/AAC.01537-06","volume":"51","author":"SH Xiao","year":"2007","unstructured":"Xiao SH, Keiser J, Chollet J, Utzinger J, Dong Y, Vennerstrom JL, Tanner M. The in vitro and in vivo activities of synthetic trioxolanes on major human schistosome species. Antimicrobial Agents Chemother. 2007;51(4):1440\u20135.","journal-title":"Antimicrobial Agents Chemother"},{"issue":"6","key":"286_CR58","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QCO.0b013e3282f19ec4","volume":"20","author":"J Keiser","year":"2007","unstructured":"Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis. 2007;20(6):605\u201312.","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"286_CR59","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/AAC.05371-11","volume":"56","author":"J Keiser","year":"2012","unstructured":"Keiser J, Ingram K, Vargas M, Chollet J, Wang X, Dong Y, Vennerstrom JL. In vivo activity of aryl ozonides against Schistosoma species. Antimicrob Agents Chemother. 2012;56(2):1090\u20132.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"286_CR60","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1128\/AAC.02394-15","volume":"60","author":"A Leonidova","year":"2016","unstructured":"Leonidova A, Vargas M, Huwyler J, Keiser J. Pharmacokinetics of the antischistosomal lead ozonide OZ418 in uninfected mice determined by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2016;60(12):7364\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"286_CR61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.actatropica.2014.12.005","volume":"143","author":"SF Mossallam","year":"2015","unstructured":"Mossallam SF, Amer EI, El-Faham MH. Efficacy of Synriam, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni. Acta Trop. 2015;143:36\u201346.","journal-title":"Acta Trop"},{"issue":"16","key":"286_CR62","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1016\/j.bmc.2015.02.010","volume":"23","author":"N Cowan","year":"2015","unstructured":"Cowan N, Yaremenko IA, Krylov IB, Terent\u2019ev AO, Keiser J. Elucidation of the in vitro and in vivo activities of bridged 1,2,4-trioxolanes, bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, silyl peroxides, and hydroxylamine derivatives against Schistosoma mansoni. Bioorg Med Chem. 2015;23(16):5175\u201381.","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"286_CR63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tmaid.2008.06.006","volume":"6","author":"L Nassauw Van","year":"2008","unstructured":"Van Nassauw L, Toovey S, Van Op den bosch J, Timmermans J-P, Vercruysse J. Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice. Travel Med Infect Dis. 2008;6(5):253\u20138.","journal-title":"Travel Med Infect Dis"},{"key":"286_CR64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/1475-2875-9-357","volume":"9","author":"P Schlagenhauf","year":"2010","unstructured":"Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J. 2010;9:357.","journal-title":"Malar J"},{"issue":"1","key":"286_CR65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000350","volume":"3","author":"J Keiser","year":"2009","unstructured":"Keiser J, Chollet J, Xiao SH, Mei JY, Jiao PY, Utzinger J, Tanner M. Mefloquine-an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis. 2009;3(1):e350.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"286_CR66","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.exppara.2010.08.011","volume":"127","author":"T Manneck","year":"2011","unstructured":"Manneck T, Braissant O, Ellis W, Keiser J. Schistosoma mansoni: antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo. Exp Parasitol. 2011;127(1):260\u20139.","journal-title":"Exp Parasitol"},{"issue":"2","key":"286_CR67","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12639-014-0489-4","volume":"40","author":"OM Abou-Shady","year":"2016","unstructured":"Abou-Shady OM, Mohammed SS, Attia SS, Yusuf HA, Helmy DO. Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in mice. J Parasit Dis. 2016;40(2):259\u201367.","journal-title":"J Parasit Dis"},{"issue":"3","key":"286_CR68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00436-009-1471-4","volume":"105","author":"SH Xiao","year":"2009","unstructured":"Xiao SH, Chollet J, Utzinger J, Mei JY, Jiao PY, Keiser J, Tanner M. Effect of single-dose oral mefloquine on the morphology of adult Schistosoma japonicum in mice. Parasitol Res. 2009;105(3):853\u201361.","journal-title":"Parasitol Res"},{"issue":"6","key":"286_CR69","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1128\/AAC.06177-11","volume":"56","author":"K Ingram","year":"2012","unstructured":"Ingram K, Ellis W, Keiser J. Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob Agents Chemother. 2012;56(6):3207\u201315.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"286_CR70","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/jac\/dkr178","volume":"66","author":"J Keiser","year":"2011","unstructured":"Keiser J, Manneck T, Vargas M. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother. 2011;66(8):1791\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"286_CR71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002610","volume":"8","author":"K Ingram-Sieber","year":"2014","unstructured":"Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, Wells TN, Spangenberg T, Keiser J. Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl Trop Dis. 2014;8(1):e2610.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"286_CR72","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/AAC.04463-14","volume":"59","author":"N Cowan","year":"2015","unstructured":"Cowan N, Datwyler P, Ernst B, Wang C, Vennerstrom JL, Spangenberg T, Keiser J. Activities of N, N\u2019-Diarylurea MMV665852 analogs against Schistosoma mansoni. Antimicrob Agents Chemother. 2015;59(4):1935\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"286_CR73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/1756-3305-7-424","volume":"7","author":"J Keiser","year":"2014","unstructured":"Keiser J, Vargas M, Rubbiani R, Gasser G, Biot C. In vitro and in vivo antischistosomal activity of ferroquine derivatives. Parasit Vectors. 2014;7:424.","journal-title":"Parasit Vectors"},{"issue":"9","key":"286_CR74","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1128\/AAC.00778-16","volume":"60","author":"MO Khan","year":"2016","unstructured":"Khan MO, Keiser J, Amoyaw PN, Hossain MF, Vargas M, Le JG, Simpson NC, Roewe KD, Freeman TN, Hasley TR, et al. Discovery of antischistosomal drug leads based on tetraazamacrocyclic derivatives and their metal complexes. Antimicrob Agents Chemother. 2016;60(9):5331\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"286_CR75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpara.2010.09.010","volume":"41","author":"MM Eissa","year":"2011","unstructured":"Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol. 2011;41(2):235\u201342.","journal-title":"Int J Parasitol"},{"key":"286_CR76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.actatropica.2016.03.038","volume":"159","author":"RM El-Moslemany","year":"2016","unstructured":"El-Moslemany RM, Eissa MM, Ramadan AA, El-Khordagui LK, El-Azzouni MZ. Miltefosine lipid nanocapsules: intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. Acta Trop. 2016;159:142\u20138.","journal-title":"Acta Trop"},{"key":"286_CR77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.actatropica.2016.11.006","volume":"166","author":"MM Eissa","year":"2016","unstructured":"Eissa MM, Mossallam SF, Amer EI, Younis LK, Rashed HA. Repositioning of chlorambucil as a potential anti-schistosomal agent. Acta Trop. 2016;166:58\u201366.","journal-title":"Acta Trop"},{"key":"286_CR78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s13071-015-1023-y","volume":"8","author":"N Cowan","year":"2015","unstructured":"Cowan N, Keiser J. Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni. Parasit Vectors. 2015;8:417.","journal-title":"Parasit Vectors"},{"issue":"6","key":"286_CR79","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4155\/fmc.15.31","volume":"7","author":"V Gelmedin","year":"2015","unstructured":"Gelmedin V, Dissous C, Grevelding CG. Re-positioning protein-kinase inhibitors against schistosomiasis. Future Med Chem. 2015;7(6):737\u201352.","journal-title":"Future Med Chem"},{"issue":"6","key":"286_CR80","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/jac\/dkv016","volume":"70","author":"J Keiser","year":"2015","unstructured":"Keiser J, Panic G, Vargas M, Wang C, Dong Y, Gautam N, Vennerstrom JL. Aryl hydantoin Ro 13\u20133978, a broad-spectrum antischistosomal. J Antimicrob Chemother. 2015;70(6):1788\u201397.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"286_CR81","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/jac\/dkq233","volume":"65","author":"J Keiser","year":"2010","unstructured":"Keiser J, Vargas M, Vennerstrom JL. Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice. J Antimicrob Chemother. 2010;65(9):1991\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"23","key":"286_CR82","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1021\/acs.jmedchem.6b01410","volume":"59","author":"C Wang","year":"2016","unstructured":"Wang C, Zhao Q, Vargas M, Jones JO, White KL, Shackleford DM, Chen G, Saunders J, Ng AC, Chiu FC, et al. Revisiting the SAR of the antischistosomal aryl hydantoin (Ro 13\u20133978). J Med Chem. 2016;59(23):10705\u201318.","journal-title":"J Med Chem"},{"issue":"8","key":"286_CR83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004928","volume":"10","author":"A Guidi","year":"2016","unstructured":"Guidi A, Lalli C, Perlas E, Bolasco G, Nibbio M, Monteagudo E, Bresciani A, Ruberti G. Discovery and characterization of novel anti-schistosomal properties of the anti-anginal drug, perhexiline and its impact on Schistosoma mansoni male and female reproductive systems. PLoS Negl Trop Dis. 2016;10(8):e0004928.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"286_CR84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003962","volume":"9","author":"G Panic","year":"2015","unstructured":"Panic G, Vargas M, Scandale I, Keiser J. Activity profile of an FDA-approved compound library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9(7):e0003962.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"286_CR85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000478","volume":"3","author":"MH Abdulla","year":"2009","unstructured":"Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, Xu F, Renslo AR, Williams J, McKerrow JH, Caffrey CR. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis. 2009;3(7):e478.","journal-title":"PLoS Negl Trop Dis"},{"issue":"15","key":"286_CR86","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2174\/0929867013371581","volume":"8","author":"J Utzinger","year":"2001","unstructured":"Utzinger J, Xiao SH, Keiser J, Chen MG, Zheng J, Tanner M. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr Med Chem. 2001;8(15):1841\u201360.","journal-title":"Curr Med Chem"},{"issue":"2","key":"286_CR87","first-page":"105","volume":"8","author":"J Utzinger","year":"2007","unstructured":"Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs. 2007;8(2):105\u201316.","journal-title":"Curr Opin Investig Drugs"},{"issue":"9","key":"286_CR88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1473-3099(10)70169-9","volume":"10","author":"J Utzinger","year":"2010","unstructured":"Utzinger J, Tanner M, Keiser J. ACTs for schistosomiasis: do they act? Lancet Infect Dis. 2010;10(9):579\u201381.","journal-title":"Lancet Infect Dis"},{"key":"286_CR89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0065-308X(10)73009-8","volume":"73","author":"SH Xiao","year":"2010","unstructured":"Xiao SH, Keiser J, Cheng MG, Tanner M, Utzinger J. Research and development of antischistosomal drugs in the People\u2019s Republic of China: a 60-year review. Adv Parasitol. 2010;73:231\u201395.","journal-title":"Adv Parasitol"},{"issue":"9","key":"286_CR90","doi-asserted-by":"crossref","first-page":"e45867","DOI":"10.1371\/journal.pone.0045867","volume":"7","author":"L Perez del Villar","year":"2012","unstructured":"Perez del Villar L, Burguillo FJ, Lopez-Aban J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One. 2012;7(9):e45867.","journal-title":"PLoS One"},{"key":"286_CR91","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.phrs.2016.02.017","volume":"110","author":"ME Saeed","year":"2016","unstructured":"Saeed ME, Krishna S, Greten HJ, Kremsner PG, Efferth T. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol Res. 2016;110:216\u201326.","journal-title":"Pharmacol Res"},{"issue":"5874","key":"286_CR92","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.1155165","volume":"320","author":"NJ White","year":"2008","unstructured":"White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320(5874):330\u20134.","journal-title":"Science"},{"key":"286_CR93","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40249-015-0091-8","volume":"4","author":"E Tambo","year":"2015","unstructured":"Tambo E, Khater EI, Chen JH, Bergquist R, Zhou XN. Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty. Infect Dis Poverty. 2015;4:58.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"286_CR94","first-page":"7","volume":"18","author":"LJ Wu","year":"1983","unstructured":"Wu LJ, Yang HZ, Yang YQ. Histological and histochemical changes of Schistosoma japonicum and host liver caused by artemether. Acta Pharmaceut Sin. 1983;18(1):7\u201314.","journal-title":"Acta Pharmaceut Sin"},{"issue":"9","key":"286_CR95","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0020-7519(00)00091-6","volume":"30","author":"SH Xiao","year":"2000","unstructured":"Xiao SH, Utzinger J, Chollet J, Endriss Y, N\u2019Goran EK, Tanner M. Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int J Parasitol. 2000;30(9):1001\u20136.","journal-title":"Int J Parasitol"},{"issue":"9212","key":"286_CR96","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(00)02114-0","volume":"355","author":"J Utzinger","year":"2000","unstructured":"Utzinger J, N\u2019Goran EK, N\u2019Dri A, Lengeler C, Xiao SH, Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 2000;355(9212):1320\u20135.","journal-title":"Lancet"},{"issue":"1","key":"286_CR97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2003.68.24","volume":"68","author":"EK N\u2019Goran","year":"2003","unstructured":"N\u2019Goran EK, Utzinger J, Gnaka HN, Yapi A, N\u2019Guessan NA, Kigbafori SD, Lengeler C, Chollet J, Xiao SH, Tanner M. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am J Trop Med Hyg. 2003;68(1):24\u201332.","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"286_CR98","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1086\/324004","volume":"184","author":"S Borrmann","year":"2001","unstructured":"Borrmann S, Szlez\u00e1k N, Faucher J-F, Matsiegui P-B, Neubauer R, Binder RK, Lell B, Kremsner PG. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis. 2001;184(10):1363\u20136.","journal-title":"J Infect Dis"},{"issue":"6","key":"286_CR99","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/QCO.0b013e32834cd3ed","volume":"24","author":"C O\u2019Brien","year":"2011","unstructured":"O\u2019Brien C, Henrich PP, Passi N, Fidock DA. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis. 2011;24(6):570\u20137.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"286_CR100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/infdis\/jiu142","volume":"210","author":"SM Taylor","year":"2014","unstructured":"Taylor SM, Juliano JJ. Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. J Infect Dis. 2014;210(3):335\u20137.","journal-title":"J Infect Dis"},{"key":"286_CR101","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.actatropica.2016.02.015","volume":"158","author":"H Elmorshedy","year":"2016","unstructured":"Elmorshedy H, Tanner M, Bergquist RN, Sharaf S, Barakat R. Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: a randomized controlled trial. Acta Trop. 2016;158:52\u20138.","journal-title":"Acta Trop"},{"issue":"4","key":"286_CR102","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4103\/2141-9248.139270","volume":"4","author":"C Patil","year":"2014","unstructured":"Patil C, Katare S, Baig M, Doifode S. Fixed dose combination of arterolane and piperaquine: a newer prospect in antimalarial therapy. Ann Med Health Sci Res. 2014;4(4):466\u201371.","journal-title":"Ann Med Health Sci Res"},{"issue":"9","key":"286_CR103","doi-asserted-by":"crossref","first-page":"e0005008","DOI":"10.1371\/journal.pntd.0005008","volume":"10","author":"B Barda","year":"2016","unstructured":"Barda B, Coulibaly JT, Puchkov M, Huwyler J, Hattendorf J, Keiser J. Efficacy and safety of moxidectin, Synriam, Synriam-praziquantel versus praziquantel against Schistosoma haematobium and S. mansoni infections: a randomized, exploratory phase 2 trial. PLoS Negl Trop Dis. 2016;10(9):e0005008.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"286_CR104","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1086\/651682","volume":"50","author":"J Keiser","year":"2010","unstructured":"Keiser J, N\u2019Guessan NA, Adoubryn KD, Silu\u00e9 KD, Vounatsou P, Hatz C, Utzinger J, N\u2019Goran EK. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis. 2010;50(9):1205\u201313.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"286_CR105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002975","volume":"8","author":"J Keiser","year":"2014","unstructured":"Keiser J, Silu\u00e9 KD, Adiossan LK, N\u2019Guessan NA, Monsan N, Utzinger J, N\u2019Goran EK. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl Trop Dis. 2014;8(7):e2975.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"286_CR106","first-page":"139","volume":"43","author":"C Genchi","year":"2001","unstructured":"Genchi C, Poglayen G, Kramer LH, Venco L, Agostini A. Efficacy of moxidectin for the prevention of adult heartworm (Dirofilaria immitis) infection in dogs. Parassitologia. 2001;43(3):139\u201341.","journal-title":"Parassitologia"},{"issue":"6","key":"286_CR107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002953","volume":"8","author":"K Awadzi","year":"2014","unstructured":"Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"286_CR108","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4269\/ajtmh.14-0328","volume":"91","author":"S Selim","year":"2014","unstructured":"Selim S, El Sagheer O, El Amir A, Barakat R, Hadley K, Bruins MJ, El Ridi R. Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt. Am J Trop Med Hyg. 2014;91(5):973\u201381.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"286_CR109","doi-asserted-by":"crossref","first-page":"797","DOI":"10.4269\/ajtmh.14-0675","volume":"92","author":"R Barakat","year":"2015","unstructured":"Barakat R, Abou El-Ela NE, Sharaf S, El Sagheer O, Selim S, Tallima H, Bruins MJ, Hadley KB, El Ridi R. Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regions. Am J Trop Med Hyg. 2015;92(4):797\u2013804.","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"286_CR110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pt.2003.09.005","volume":"19","author":"A Fenwick","year":"2003","unstructured":"Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol. 2003;19(11):509\u201315.","journal-title":"Trends Parasitol"},{"issue":"2","key":"286_CR111","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/S1473-3099(16)30535-7","volume":"17","author":"NC Lo","year":"2017","unstructured":"Lo NC, Addiss DG, Hotez PJ, King CH, Stothard JR, Evans DS, Colley DG, Lin W, Coulibaly JT, Bustinduy AL, et al. A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now. Lancet Infect Dis. 2017;17(2):e64\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"286_CR112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004946","volume":"10","author":"AL Bustinduy","year":"2016","unstructured":"Bustinduy AL, Friedman JF, Kjetland EF, Ezeamama AE, Kabatereine NB, Stothard JR, King CH. Expanding praziquantel (PZQ) access beyond mass drug administration programs: paving a way forward for a pediatric PZQ formulation for schistosomiasis. PLoS Negl Trop Dis. 2016;10(9):e0004946.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"286_CR113","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1473-3099(15)00345-X","volume":"16","author":"RM Olveda","year":"2016","unstructured":"Olveda RM, Acosta LP, Tallo V, Baltazar PI, Lesiguez JL, Estanislao GG, Ayaso EB, Monterde DB, Ida A, Watson N, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(2):199\u2013208.","journal-title":"Lancet Infect Dis"},{"key":"286_CR114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13071-015-1244-0","volume":"9","author":"S Knopp","year":"2016","unstructured":"Knopp S, Person B, Ame SM, Ali SM, Muhsin J, Juma S, Khamis IS, Rabone M, Blair L, Fenwick A, et al. Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey. Parasit Vectors. 2016;9:5.","journal-title":"Parasit Vectors"},{"issue":"Suppl 1","key":"286_CR115","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.actatropica.2010.11.006","volume":"120","author":"QB Hong","year":"2011","unstructured":"Hong QB, Yang K, Huang YX, Sun LP, Yang GJ, Gao Y, Gao Y, Zhang LH, Zhou M, Steinmann P, et al. Effectiveness of a comprehensive schistosomiasis japonica control program in Jiangsu province, China, from 2005 to 2008. Acta Trop. 2011;120 Suppl 1:S151\u20137.","journal-title":"Acta Trop"},{"issue":"6","key":"286_CR116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000244","volume":"2","author":"R Bergquist","year":"2008","unstructured":"Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis. 2008;2(6):e244.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"286_CR117","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s13071-016-1799-4","volume":"9","author":"BM Tebeje","year":"2016","unstructured":"Tebeje BM, Harvie M, You H, Loukas A, McManus DP. Schistosomiasis vaccines: where do we stand? Parasit Vectors. 2016;9(1):528.","journal-title":"Parasit Vectors"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-017-0286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T19:46:05Z","timestamp":1658864765000},"score":1,"resource":{"primary":{"URL":"http:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-017-0286-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1186\/s40249-017-0286-2","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]},"article-number":"74"}}